Effect of thiazolidinediones and insulin on cognitive outcomes in ACCORD-MIND

Elizabeth R. Seaquist, Michael E. Miller, Vivian Fonseca, Faramarz Ismail-Beigi, Lenore J. Launer, Zubin Punthakee, Ajay Sood

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Objective To examine the relationship of cognitive performance to exposure to insulin (INS) and thiazolidinediones (TZD) in the ACCORD-MIND cohort. Methods Participants (55-80 years) with type 2 diabetes (T2D), hemoglobin A1c (HbA1c) > 7.5% (> 58 mmol/mol), and a high risk of cardiovascular events were randomly assigned to receive intensive control targeting HbA1c to < 6.0% (42 mmol/mol) or a standard strategy targeting HbA1c to 7.0%-7.9% (53-63 mmol/mol). The Digit Symbol Substitution Test (DSST) was assessed at baseline and at 20 and 40 months. Exposure to INS was calculated as average daily dose/kg of body weight; exposure to rosiglitazone (ROS) was calculated as days of ROS prescription in the intervals preceding the 20- and 40-month DSSTs. Results At baseline, INS use was associated with reduced DSST performance, but not after controlling for comorbidities and lab values. There was no relationship between use of a TZD and DSST performance on at baseline. ROS but not INS exposure was associated with greater decline in DSST performance over 40 months in subjects randomized to the intensive but not the standard group. Conclusions Exposure to a TZD may increase cognitive decline in some patients with T2D. However, these results may be confounded by unexplained differences between participants.

Original languageEnglish (US)
Pages (from-to)485-491
Number of pages7
JournalJournal of Diabetes and its Complications
Volume27
Issue number5
DOIs
StatePublished - Sep 1 2013
Externally publishedYes

Fingerprint

rosiglitazone
Thiazolidinediones
Insulin
Hemoglobins
Type 2 Diabetes Mellitus
Prescriptions
Comorbidity
Body Weight

Keywords

  • Cognition
  • Diabetes
  • Insulin
  • Thiazolidinediones

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Seaquist, E. R., Miller, M. E., Fonseca, V., Ismail-Beigi, F., Launer, L. J., Punthakee, Z., & Sood, A. (2013). Effect of thiazolidinediones and insulin on cognitive outcomes in ACCORD-MIND. Journal of Diabetes and its Complications, 27(5), 485-491. https://doi.org/10.1016/j.jdiacomp.2013.03.005

Effect of thiazolidinediones and insulin on cognitive outcomes in ACCORD-MIND. / Seaquist, Elizabeth R.; Miller, Michael E.; Fonseca, Vivian; Ismail-Beigi, Faramarz; Launer, Lenore J.; Punthakee, Zubin; Sood, Ajay.

In: Journal of Diabetes and its Complications, Vol. 27, No. 5, 01.09.2013, p. 485-491.

Research output: Contribution to journalArticle

Seaquist, ER, Miller, ME, Fonseca, V, Ismail-Beigi, F, Launer, LJ, Punthakee, Z & Sood, A 2013, 'Effect of thiazolidinediones and insulin on cognitive outcomes in ACCORD-MIND', Journal of Diabetes and its Complications, vol. 27, no. 5, pp. 485-491. https://doi.org/10.1016/j.jdiacomp.2013.03.005
Seaquist ER, Miller ME, Fonseca V, Ismail-Beigi F, Launer LJ, Punthakee Z et al. Effect of thiazolidinediones and insulin on cognitive outcomes in ACCORD-MIND. Journal of Diabetes and its Complications. 2013 Sep 1;27(5):485-491. https://doi.org/10.1016/j.jdiacomp.2013.03.005
Seaquist, Elizabeth R. ; Miller, Michael E. ; Fonseca, Vivian ; Ismail-Beigi, Faramarz ; Launer, Lenore J. ; Punthakee, Zubin ; Sood, Ajay. / Effect of thiazolidinediones and insulin on cognitive outcomes in ACCORD-MIND. In: Journal of Diabetes and its Complications. 2013 ; Vol. 27, No. 5. pp. 485-491.
@article{6763946572ae44e687e48f24a58ccd50,
title = "Effect of thiazolidinediones and insulin on cognitive outcomes in ACCORD-MIND",
abstract = "Objective To examine the relationship of cognitive performance to exposure to insulin (INS) and thiazolidinediones (TZD) in the ACCORD-MIND cohort. Methods Participants (55-80 years) with type 2 diabetes (T2D), hemoglobin A1c (HbA1c) > 7.5{\%} (> 58 mmol/mol), and a high risk of cardiovascular events were randomly assigned to receive intensive control targeting HbA1c to < 6.0{\%} (42 mmol/mol) or a standard strategy targeting HbA1c to 7.0{\%}-7.9{\%} (53-63 mmol/mol). The Digit Symbol Substitution Test (DSST) was assessed at baseline and at 20 and 40 months. Exposure to INS was calculated as average daily dose/kg of body weight; exposure to rosiglitazone (ROS) was calculated as days of ROS prescription in the intervals preceding the 20- and 40-month DSSTs. Results At baseline, INS use was associated with reduced DSST performance, but not after controlling for comorbidities and lab values. There was no relationship between use of a TZD and DSST performance on at baseline. ROS but not INS exposure was associated with greater decline in DSST performance over 40 months in subjects randomized to the intensive but not the standard group. Conclusions Exposure to a TZD may increase cognitive decline in some patients with T2D. However, these results may be confounded by unexplained differences between participants.",
keywords = "Cognition, Diabetes, Insulin, Thiazolidinediones",
author = "Seaquist, {Elizabeth R.} and Miller, {Michael E.} and Vivian Fonseca and Faramarz Ismail-Beigi and Launer, {Lenore J.} and Zubin Punthakee and Ajay Sood",
year = "2013",
month = "9",
day = "1",
doi = "10.1016/j.jdiacomp.2013.03.005",
language = "English (US)",
volume = "27",
pages = "485--491",
journal = "Journal of Diabetes and its Complications",
issn = "1056-8727",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Effect of thiazolidinediones and insulin on cognitive outcomes in ACCORD-MIND

AU - Seaquist, Elizabeth R.

AU - Miller, Michael E.

AU - Fonseca, Vivian

AU - Ismail-Beigi, Faramarz

AU - Launer, Lenore J.

AU - Punthakee, Zubin

AU - Sood, Ajay

PY - 2013/9/1

Y1 - 2013/9/1

N2 - Objective To examine the relationship of cognitive performance to exposure to insulin (INS) and thiazolidinediones (TZD) in the ACCORD-MIND cohort. Methods Participants (55-80 years) with type 2 diabetes (T2D), hemoglobin A1c (HbA1c) > 7.5% (> 58 mmol/mol), and a high risk of cardiovascular events were randomly assigned to receive intensive control targeting HbA1c to < 6.0% (42 mmol/mol) or a standard strategy targeting HbA1c to 7.0%-7.9% (53-63 mmol/mol). The Digit Symbol Substitution Test (DSST) was assessed at baseline and at 20 and 40 months. Exposure to INS was calculated as average daily dose/kg of body weight; exposure to rosiglitazone (ROS) was calculated as days of ROS prescription in the intervals preceding the 20- and 40-month DSSTs. Results At baseline, INS use was associated with reduced DSST performance, but not after controlling for comorbidities and lab values. There was no relationship between use of a TZD and DSST performance on at baseline. ROS but not INS exposure was associated with greater decline in DSST performance over 40 months in subjects randomized to the intensive but not the standard group. Conclusions Exposure to a TZD may increase cognitive decline in some patients with T2D. However, these results may be confounded by unexplained differences between participants.

AB - Objective To examine the relationship of cognitive performance to exposure to insulin (INS) and thiazolidinediones (TZD) in the ACCORD-MIND cohort. Methods Participants (55-80 years) with type 2 diabetes (T2D), hemoglobin A1c (HbA1c) > 7.5% (> 58 mmol/mol), and a high risk of cardiovascular events were randomly assigned to receive intensive control targeting HbA1c to < 6.0% (42 mmol/mol) or a standard strategy targeting HbA1c to 7.0%-7.9% (53-63 mmol/mol). The Digit Symbol Substitution Test (DSST) was assessed at baseline and at 20 and 40 months. Exposure to INS was calculated as average daily dose/kg of body weight; exposure to rosiglitazone (ROS) was calculated as days of ROS prescription in the intervals preceding the 20- and 40-month DSSTs. Results At baseline, INS use was associated with reduced DSST performance, but not after controlling for comorbidities and lab values. There was no relationship between use of a TZD and DSST performance on at baseline. ROS but not INS exposure was associated with greater decline in DSST performance over 40 months in subjects randomized to the intensive but not the standard group. Conclusions Exposure to a TZD may increase cognitive decline in some patients with T2D. However, these results may be confounded by unexplained differences between participants.

KW - Cognition

KW - Diabetes

KW - Insulin

KW - Thiazolidinediones

UR - http://www.scopus.com/inward/record.url?scp=84883782238&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883782238&partnerID=8YFLogxK

U2 - 10.1016/j.jdiacomp.2013.03.005

DO - 10.1016/j.jdiacomp.2013.03.005

M3 - Article

C2 - 23680059

AN - SCOPUS:84883782238

VL - 27

SP - 485

EP - 491

JO - Journal of Diabetes and its Complications

JF - Journal of Diabetes and its Complications

SN - 1056-8727

IS - 5

ER -